Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249784 | 0.87 | KMT2A (0.47) | CNR2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13249829 | 0.85 | KMT2A (0.44) | GRM5KMT2ALMNAP2RX7 | |
| SCHEMBL13249785 | 0.85 | CYP2D6 (0.43) | LMNAP2RX7 | |
| SCHEMBL13249769 | 0.84 | PARP1 (0.48) | P2RX3 | |
| SCHEMBL13249831 | 0.83 | MTHFD2 (0.46) | GRM5P2RX7 | |
| SCHEMBL13249933 | 0.83 | KMT2A (0.37) | MEN1KMT2ALMNAP2RX7 | |
| SCHEMBL13249832 | 0.83 | TRPV1 (0.48) | NPC1RAB9APDE10AKMT2ASMN1; SMN2 | |
| SCHEMBL13249856 | 0.82 | PTGDR2 (0.38) | CNR1CNR2KMT2ALMNAP2RX7 | |
| SCHEMBL13249920 | 0.82 | ROCK2 (0.37) | KMT2ALMNAP2RX7 | |
| SCHEMBL13249848 | 0.82 | ALDH1A1 (0.46) | CNR1CNR2GRM5LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | CNR1 150/4885P2RX3 162/4885CNR2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.